Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated
详细信息 查看全文
- 作者：Ramzi Abboud1 ; &dagger ; ; Jesse Keller1 ; &dagger ; ; Michael Slade1 ; &dagger ; ; John F. DiPersio1 ; Peter Westervelt1 ; Michael P. Rettig1 ; Stephanie Meier1 ; Todd A. Fehniger1 ; Camille N. Abboud1 ; Geoffrey L. Uy1 ; Ravi Vij1 ; Kathryn M. Trinkaus2 ; Mark A. Schroeder1 ; Rizwan Romee1 ; rromee@wustl.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Cytokine-release syndrome (CRS) ; Haploidentical ; Tocilizumab ; Transplantation-related mortality (TRM)
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：22
- 期：10
- 页码：1851-1860
- 全文大小：751 K
文摘
- •
Peripheral blood haploidentical hematopoietic cell transplantation patients frequently develop signs and symptoms consistent with cytokine-release syndrome, previously described with the use of cellular therapies, including chimeric antigen receptor T cells.
- •
Some of these patients develop severe cytokine-release syndrome and need aggressive supportive care
- •
Severe cytokine-release syndrome is associated with poor survival and delayed neutrophil engraftment
- •
Anti–IL-6 therapy is safe and well tolerated and may be an effective treatment for haploidentical hematopoietic cell transplantation–related cytokine-release syndrome